Adrienne Monson – Lifestyle
Author:
Sionna Therapeutics, Inc.
Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis
April 27, 2026
Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium
April 7, 2026